Now researchers are testing a new device that may make testing easier and may lead to a diagnosis earlier....

This unique initiative to screen for Alzheimer's disease in community settings involves a strong partnership between optometry clinics and the Alzheimer Society of Toronto...

An estimated 6.5 million Americans are currently living with Alzheimer’s. Currently, there is no cure, few effective treatments, and the only way to diagnose it is with an expensive PET scan or a painful lumbar puncture which measures spinal fluid...

Early detection and accurate diagnosis are key to getting people on the right care and treatment path—and tools such as retinal imaging can aid both patients and physicians in that journey, says Rebecca Edelmayer...

A company called RetiSpec, backed in part by the foundation, is developing a retinal test that detects neurodegenerative changes. “The eye is the window to the brain,” explains Fillit...

The Alzheimer's Drug Discovery Foundation (ADDF) announces the second phase of its Diagnostics Accelerator with new philanthropic partners and an additional $50 million in financial commitments, bringing the total capital to $100 million earmarked to speed development of new and innovative tests for early diagnosis of Alzheimer's disease and related dementias.

As a graduate student, Cindi Morshead figured out where stem cells could be hiding in the brain. Now, as scientists mark World Brain Day, she explains how gene therapies could soon regrow neurons lost to stroke and give patients reason to hope...

As more therapies potentially enter the market to treat Alzheimer’s disease, it will be imperative to use new technology to confirm diagnosis, Cohen said. “You wouldn’t give someone chemotherapy unless you confirmed they had cancer,” she said. “Times are changing with Alzheimer’s disease, matching the technology of diagnostics with what’s going on with therapeutics is an ideal pairing.”...

Progressive Medical Research is using a revolutionary retinal scanning process by RetiSpec. The scanning process has the ability to detect the early stages of Alzheimer’s...

An innovative new project in Toronto will combine optometry and community-based cognitive testing to improve Alzheimer’s screening and enable the early detection of the progressive neurodegenerative disorder. The project — launching in Ontario, Canada — will be led by the medical imaging company RetiSpec and the community-based medical center Toronto Memory Program...

RetiSpec and Toronto Memory Program are One of Twelve Select Recipients of the Inaugural Global Davos Alzheimer's Collaborative Grant Program for Healthcare System Preparedness...

This project will provide a robust and informative model that can be scaled across Canada as well as to global jurisdictions and is uniquely positioned to strengthen and better prepare our healthcare systems...

"RetiSpec's technology can be used to rapidly and noninvasively screen people during their routine eye exams, offering an easy, accessible, and scalable alternative to current methods of Alzheimer's disease detection," Eliav Shaked, CEO, and Co-founder of RetiSpec said...

The Davos Alzheimer’s Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer’s disease, today announced the recipients of a grant program aiming for early detection of cognitive symptoms...

RetiSpec and retinal imaging in general, could have an extremely positive impact on the AD community, Sharon Cohen, MD, FRCPC, believes. Cohen, a neurologist and assistant professor at the University of Toronto, led the validation study of RetiSpec... 

Developments in non-invasive retinal imaging technologies, such as RetiSpec, have provided a means to study neuronal and vascular structures in the retina in people with AD. In a validation study, RetiSpec’s hyperspectral retinal imaging was effective... 

Sharon Cohen, MD, FRCPC, lead investigator of a validation study that looked at RetiSpec, believes these types of approaches hold immense potential in the drug development field. Despite the increasing amount of funds poured into the therapeutic... 

 RetiSpec’s hyperspectral retinal imaging system is adding to the promise of these approaches, most recently with positive data presented at the 14th Clinical Trials in Alzheimer Disease Conference, November 9-12, 2021. In a cohort of 108 participants...

Although investigational, lead author Sharon Cohen, MD, believes there is great potential for retinal approaches such as those being taken by RetiSpec. Cohen, a neurologist and assistant professor at the University of Toronto, sat down with...

At the 14th Clinical Trials on Alzheimer’s Disease Conference (CTAD), November 9-12, 2021, investigators presented research that demonstrated RetiSpec’s ability to predict brain amyloid status. In a cross-sectional validation study, 108 patients who... 

As attention turns to new drugs that can address the growing burden of Alzheimer’s disease (AD) in an aging global population, Retispec Inc. has developed a noninvasive test that may be able to detect early signs of the neurodegenerative...

Gentex Corporation is the presenting sponsor of this year's Michigan International Auto Show and they're also leaders when it comes to automotive technology. They're starting to take their automotive expertise into new markets as well...

To mark January as Alzheimer’s Awareness Month, we’re joined by Sharon Cohen, a neurologist who runs Canada’s busiest memory clinic, in Toronto... 

A huge benefit of RetiSpec and other early-detection tools is that they are inexpensive, non-invasive and quick. Currently, Alzheimer’s is diagnosed with lumbar punctures, cognitive tests and PET scans...

We’ve all heard the statistics: Today, nearly 55 million people suffer from Alzheimer’s disease or related dementias. According to the WHO, dementia is the fastest growing burden on healthcare systems...

The approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, more investment and better diagnostics may be needed, explains Ben Hargreaves...

Billionaire philanthropist speaks of the new breakthroughs in diagnostics that are being conducted through Diagnostic Accelerator, a venture that raises philanthropic capital for research in this field...

New breakthroughs in Alzheimer’s diagnostics may someday soon let us substantially alter the course of the disease...

Dr. Karen Cross was doing everything in her power to prevent her diabetic grandfather from needing an amputation. But that power was limited by distance — Cross works in Toronto and her grandfather was in rural Newfoundland...

With disease-modifying treatments for Alzheimer’s disease potentially on the cusp of approval, there will be pressing demand for quick...

Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who are contributing to GAP’s Bio-Hermes Study...

Toronto-based biomedical engineers Eliav Shaked and Roy Kirshon are working on a quick, non-invasive retinal diagnostic for patients decades away from showing symptoms of dementia...

RetiSpec (Toronto, Canada) is an AI medical imaging company developing tools for the early detection of disease biomarkers in the eye.

RetiSpec's technology uses a device to perform a simple eye scan, which then can be used to identify the presence of certain disease biomarkers ...

By harnessing hyperspectral imagery, RetiSpec's patented technology allows for the rapid, simple and cost-effective identification of ...

“In collaboration with our industry partner, RetiSpec, we hope to accelerate clinical development of this early detection technique and provide existing or new treatments the best chance for success,” added Vince. This study was funded by the...

RetiSpec technology is hoped to be able to match this early detection ability without the shortcomings of the other approaches. Eliav Shaked, ...

Disruptive Technology Harnesses Hyperspectral Imagery and Machine-Learning to Allow for Rapid and Cost-Effective Identification of Alzheimer's Biomarkers ...

Could a simple eye exam detect signs of Alzheimer's disease?

RetiSpec's technology is designed to identify Alzheimer's biomarkers years before the emergence of clinical symptoms.

A new intiative from the Toronto Memory Project is trying to use retina scans to determine if patient's have Alzheimer's disease

CABHI is working with RetiSpec to accelerate its technology in Ontario and Canada. Through the Industry Innovation Partnership Program (I2 P2 ), CABHI matched RetiSpec with the Toronto Memory Program, a medical facility with one of...

The University of Minnesota and Toronto-based medical imaging company RetiSpec have announced a collaboration and licensing

The collaboration provides RetiSpec, a startup based in Toronto, Canada, with exclusive access to an imaging system developed by researchers ...

University of Minnesota researchers have developed technology to detect early signs of Alzheimer's. Utilizing the non-invasive technology, researchers from the Center for Drug Design were able to visualize clear patterns of changes suggesting the...